English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Thyroid Eye Disease Drug Meets Primary Endpoint for Proptosis Reduction
Top-line results from the OPTIC trial showed that the phase 3 study met its primary endpoint, demonstrating that more patients with active thyroid eye disease assigned teprotumumab experienced a meaningful improvement in proptosis, or protrusion of the eyeball, compared with patients assigned placebo, according to a press release from Horizon Pharma.
In the study, designed to investigate the efficacy, tolerability and safety of teprotumumab in patients with active thyroid eye disease, researchers assigned 83 patients to teprotumumab or placebo in eight IV infusions (10 mg/kg for the first infusion followed by 20 mg/kg for the remaining seven infusions) every 3 weeks for 21 weeks, according to the release. The primary endpoint was a 2 mm or more reduction of proptosis in the study eye, without deterioration in the fellow eye, at week 24. Proptosis is the main cause of morbidity in thyroid eye disease.
myBinderRelated Content
-
FDA Committee Unanimously Recommends Approval of Teprotumumab for Thyroid Eye DiseaseThe Dermatologic and Ophthalmic Drugs Ad...
-
Selenium in Graves Hyperthyroidism and OrbitopathyPurpose: To review the in vitro and in ...
-
Effects of Treatment Modalities for Graves’ Hyperthyroidism on Graves’ Orbitopathy: A 2015 Italian Society of En...Graves’ disease is the most frequent f...
-
TEPEZZA (teprotumumab-trbw)- Frequently Asked Questions1. What is TEPEZZA? TEPEZZA is the firs...
-
Controversies in Thyroidology: Spring 2020 Meeting of the American Thyroid AssociationUpdate : The American Thyroid Associatio...
-
University of California San Francisco Thyroid ClinicAt University of California, San Francis...
-
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thy...Background: Thyrotoxicosis has multip...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Brought to you by
Supported through an independent
educational grant by
